Patents by Inventor Fumie Takahashi
Fumie Takahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932021Abstract: A recording apparatus includes a tank including a chamber configured to store liquid to be supplied to a recording head that ejects the liquid and a filling port from which the liquid is injected into the chamber, and an injection auxiliary member configured to assist injecting of the liquid into the chamber from the filling port, the injection auxiliary member including a first and a second flow channels each defined by a first or a second upper end portion that opens toward outside of the tank and a first or a second lower end portion that opens toward inside of the tank, wherein the second flow channel has an expansion portion arranged in a middle portion between the second upper end portion and the second lower end portion and configured to form a step to expand a cross-sectional area.Type: GrantFiled: December 20, 2022Date of Patent: March 19, 2024Assignee: Canon Kabushiki KaishaInventors: Yusuke Naratani, Koya Iwakura, Hideaki Matsumura, Tetsu Hamano, Nobuhiro Toki, Daiju Takeda, Fumie Kameyama, Koki Shimada, Shota Asada, Ken Takenaga, Yusuke Tanaka, Yuta Araki, Taiji Maruyama, Atsushi Matsuyama, Kousuke Tanaka, Toshimitsu Takahashi, Nanae Uchinuno
-
Patent number: 8912180Abstract: Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3K? selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3K? selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.Type: GrantFiled: February 8, 2013Date of Patent: December 16, 2014Assignee: Astellas Pharma Inc.Inventors: Fumie Takahashi, Sunao Imada, Toru Asano, Yoshihiro Kozuki, Junko Maeda, Koji Kato, Hidehiko Fukahori, Masahiko Shiwaku
-
Publication number: 20120165309Abstract: [Object] A novel and excellent method for preventing or treating rejection in the transplantation of various organs, allergy diseases, autoimmune diseases, hematologic tumor, or the like, based on a PI3K?-selective inhibitory action and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), is provided [Means for Solution] It was found that a 3-substituted triazine or 3-substituted pyrimidine derivative exhibits a PI3K?-selective inhibitory action, and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and can be an agent for preventing or treating rejection in the transplantation of various organs, allergy diseases (asthma, atopic dermatitis, etc.), autoimmune diseases (rheumatoid arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus, etc.), hematologic tumor (leukemia etc.Type: ApplicationFiled: February 10, 2010Publication date: June 28, 2012Applicant: Astellas Pharma Inc.Inventors: Fumie Takahashi, Sunao Imada, Masahiko Shiwaku, Yasumasa Shiwaku, Atsuko Shiwaku, Koji Kato, Hidehiko Fukahori
-
Patent number: 8163767Abstract: The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y? are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.Type: GrantFiled: July 13, 2006Date of Patent: April 24, 2012Assignee: Astellas Pharma Inc.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Yutaka Nakajima, Keiko Hatanaka, Shohei Shirakami, Hiroshi Sasaki, Akira Tanaka, Fumie Takahashi, Koichiro Mukoyoshi, Yasuyuki Higashi, Akira Okimoto, Takeshi Hondo, Hitoshi Sawada
-
Publication number: 20110230467Abstract: [Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.Type: ApplicationFiled: November 20, 2009Publication date: September 22, 2011Applicant: Astellas Pharma Inc.Inventors: Shohei Shirakami, Fumie Takahashi, Yutaka Nakajima, Hirofumi Omura, Naohiro Aoyama, Hiroshi Sasaki, Takeshi Hondo, Hiroaki Tominaga
-
Publication number: 20110039822Abstract: The present invention provides a compound having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. As a result of studies on a novel condensed heterocyclic derivative, the inventors have found that a compound having a cross-linked structure has an excellent JAK3 inhibition activity, and have completed the present invention. In other words, it is verified that the compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g.Type: ApplicationFiled: October 28, 2010Publication date: February 17, 2011Applicant: Astellas Pharma Inc.Inventors: Takayuki INOUE, Akira Tanaka, Kazuo Nakai, Hiroshi Sasaki, Fumie Takahashi, Shohei Shirakami, Keiko Hatanaka, Yutaka Nakajima, Koichiro Mukoyoshi, Hisao Hamaguchi, Shigeki Kunikawa, Yasuyuki Higashi
-
Patent number: 7879844Abstract: The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).Type: GrantFiled: December 25, 2006Date of Patent: February 1, 2011Assignee: Astellas Pharma Inc.Inventors: Takayuki Inoue, Akira Tanaka, Kazuo Nakai, Hiroshi Sasaki, Fumie Takahashi, Shohei Shirakami, Keiko Hatanaka, Yutaka Nakajima, Koichiro Mukoyoshi, Hisao Hamaguchi, Shigeki Kunikawa, Yasuyuki Higashi
-
Publication number: 20100216798Abstract: There is provided fused heterocycles of imidazopyridazine or pyrazolopyrimidine derivative represented by the formula (I), which have excellent Lck inhibitory activity and are useful for a medicament particularly an immunosuppressive agent. [wherein one of Y and Z is C atom, and the other is N atom; —X— is —N(R1)— or the like, —R1 represents hydrogen or the like, -A- represents bond or the like, —R2 is cycloalkyl, aryl or the like, -E- is bond or the like, —R3 is aryl, aromatic heterocycle or the like, —R4, —R5 and —R6 are the same or different, each being hydrogen or the like.Type: ApplicationFiled: July 27, 2006Publication date: August 26, 2010Applicant: ASTELLAS PHARMA INCInventors: Kazuo Nakai, Fumie Takahashi, Kazuya Fujita, Yoshihiro Kozuki, Koichiro Mukoyoshi, Masamichi Inami, Norio Asai
-
Publication number: 20090270376Abstract: The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).Type: ApplicationFiled: December 25, 2006Publication date: October 29, 2009Applicant: Astellas Pharma Inc.Inventors: Takayuki Inoue, Akira Tanaka, Kazuo Nakai, Hiroshi Sasaki, Fumie Takahashi, Shohei Shirakami, Keiko Hatanaka, Yutaka Nakajima, Koichiro Mukoyoshi, Hisao Hamaguchi, Shigeki Kunikawa, Yasuyuki Higashi
-
Publication number: 20090264399Abstract: The invention relates to compound of the formula (I) or its salt, wherein —R1, —R2, —R3, —R4, —R5, -M-, —X— and —Y? are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.Type: ApplicationFiled: July 13, 2006Publication date: October 22, 2009Applicant: Astellas Pharma Inc.Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Yutaka Nakajima, Keiko Hatanaka, Shohei Shirakami, Hiroshi Sasaki, Akira Tanaka, Fumie Takahashi, Koichiro Mukoyoshi, Yasuyuki Higashi, Akira Okimoto, Takeshi Hondo, Hitoshi Sawada
-
Publication number: 20070043084Abstract: A compound of the formula (1): wherein R1 is cyano, and the like; R2 is hydroxy, and the like; R3 is (lower)alkoxy, and the like; X and Y are each CH or N; or pharmaceutically acceptable salts thereof, which are useful as a medicament.Type: ApplicationFiled: April 26, 2004Publication date: February 22, 2007Applicant: Astellas Pharma Inc.Inventors: Fumie Takahashi, Tadashi Terasaka, Masataka Morita, Nobukiyo Konishi, Katsuya Nakamura
-
Publication number: 20040266774Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): 1Type: ApplicationFiled: June 14, 2004Publication date: December 30, 2004Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Kiyotaka Ito, Glen W. Spears, Fumie Takahashi, Akira Yamada, Masaki Tomishima, Hiroshi Miyake
-
Patent number: 6770667Abstract: The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): wherein R1 is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group, R2 is a hydrogen atom or a lower alkyl group, and R3 is a fluorenyl group. The compound of formula (I) includes pharmaceutically acceptable salts: The compound of formula (I) and salts thereof have 5-HT antagonism activity.Type: GrantFiled: March 21, 2002Date of Patent: August 3, 2004Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Kiyotaka Ito, Glen W. Spears, Fumie Takahashi, Akira Yamada, Masaki Tomishima, Hiroshi Miyake
-
Patent number: 6384028Abstract: &bgr;-alanine compounds or a pharmaceutically acceptable salt thereof, which is useful as a glycoprotein IIB/IIIa antagonist, inhibitor of blood platelet aggregation and inhibitor of the binding of fibrinogen to blood platelet; a composition containing the same, a process for the preparation of the compound, and a process for the treatment of diseases caused by thrombus formation, for example, are provided.Type: GrantFiled: September 10, 1997Date of Patent: May 7, 2002Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Mitsuru Ohkubo, Fumie Takahashi, Toshio Yamanaka, Masayuki Kato
-
Patent number: 6380215Abstract: This invention relates to &bgr;-alanine derivatives represented by the following formula: wherein each symbol is as defined in the specification and pharmaceutically acceptable salt thereof which is glycoprotein IIb/IIIa antagonist, inhibitor of blood platelets aggregation and inhibitor of the binding of fibrinogen to blood platelets, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.Type: GrantFiled: August 4, 1995Date of Patent: April 30, 2002Assignee: Fujisawa Pharmaceutical Co., LtdInventors: Mitsuru Ohkubo, Fumie Takahashi, Toshio Yamanaka, Hiroyoshi Sakai, Masayuki Kato
-
Publication number: 20010051730Abstract: This invention relates to &bgr;-alanine derivatives represented by the following formula: 1Type: ApplicationFiled: May 29, 2001Publication date: December 13, 2001Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Ohkubo, Fumie Takahashi, Toshio Yamanaka, Hiroyoshi Sakai, Masayuki Kato
-
Publication number: 20010016571Abstract: This invention relates to &bgr;-alanine derivative represented by the following formula (I); 1Type: ApplicationFiled: March 15, 2001Publication date: August 23, 2001Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Ohkubo, Fumie Takahashi, Toshio Yamanaka, Masayuki Kato